Bapineuzumab Antibody is a research-grade biosimilar monoclonal antibody targeting AICD-57. It is a humanized IgG1-nd antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi).
Product Name:
Bapineuzumab Antibody
SKU:
GXBS00337
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
A4
Isotype:
IgG1-nd
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
AAB-001, 648895-38-9
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
